Formulary Search

Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.

Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.

Reserve for patients who are unable to swallow tablets.

Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.

Oro-dispersible tablets are more cost effective than oral solution. Reserve oral solution for use in patients where the required dose is not available in an oro-dispersible form.

Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.

Initiation by a mental health specialist and stabilisation for at least 1 month before any request to transfer prescribing responsibility.

Off-label use.

Initiation by a mental health specialist and stabilisation for at least 1 month before any request to transfer prescribing responsibility.

Capsules are an unlicensed product.

Prescribe by BRAND. Lithium carbonate and lithium citrate are not equivalent.

Initiation and stabilisation by the specialist mental health team for at least 1 month before any request to transfer prescribing responsibility to primary care.

Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.

Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.

Reserve orodispersible tablets for patients with swallowing difficulties or administration via a PEG tube. 

Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.

Oral lyophilisates are considerably more expensive than orodispersible tablets.
Orodispersible tablets should be used in preference to oral lyophilisates

Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.

Initiation by a Mental Health specialist and stabilisation for a minimum of 1 month before any request to transfer prescribing responsibility.

Only for use where the liquid formulation is unsuitable e.g. for supervised administration to ensure compliance.

Off-label use. Licesned product is valproic acid (valproate semisodium).

Initiation and stabilisation by the mental health specialist team for at least 1 month before any request for transfer of prescribing responsbility to primary care.

See separate formulary entry for sodium valproate in people WITH childbearing potential - important pregnancy-prevention requirement.

Initiation and stabilisation by the mental health specialist team for at least 1 month before any request for transfer of prescribing responsbility to primary care.

See separate formulary entry for valproic acid in people WITH childbearing potential - important pregnancy-prevention requirement.

Off-label use. Licesned product is valproic acid (valproate semisodium).

Initiation and stabilisation by the mental health specialist team for at least 1 month before any request for transfer of prescribing responsbility to primary care.

Pregnancy prevention requirement - refer to additional information on the PAD (click on drug name to access)

Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136

Initiation and stabilisation by the mental health specialist team for at least 1 month before any request for transfer of prescribing responsbility to primary care.

Pregnancy prevention requirement - refer to additional information on the PAD (click on drug name to access)

Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136

For prescribing by SABP clinicians only.

Asenapine sublingual tablets have been discontinued and should not be initiated in new patients. Supplies of unlicensed asenapine may be available but additional guidance applies to the prescribing of unlicensed and imported medicines. Existing patients should be reviewed and switched where possible, to a suitable licensed alternative.